Mirae Asset Global Investments Co. Ltd. Sells 121 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,615 shares of the company’s stock after selling 121 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Axsome Therapeutics were worth $140,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AXSM. FMR LLC increased its stake in Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC boosted its holdings in Axsome Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after purchasing an additional 23,564 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after purchasing an additional 8,125 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Axsome Therapeutics by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock worth $28,992,000 after buying an additional 12,778 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its position in shares of Axsome Therapeutics by 11.0% during the 3rd quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock worth $26,834,000 after buying an additional 29,497 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Up 0.1 %

NASDAQ:AXSM opened at $131.68 on Friday. The company has a market cap of $6.38 billion, a price-to-earnings ratio of -20.17 and a beta of 1.05. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The stock’s fifty day moving average price is $96.55 and its two-hundred day moving average price is $92.67. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. On average, analysts anticipate that Axsome Therapeutics, Inc. will post -4.7 EPS for the current year.

Analyst Ratings Changes

AXSM has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Mizuho upped their target price on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $190.00 target price on shares of Axsome Therapeutics in a research report on Tuesday. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $139.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $147.13.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.